Heron Therapeutics (HRTX) Total Current Liabilities (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Total Current Liabilities came in at $90.5 million in Q1 2026, up 2.21% YoY from $88.6 million in Q1 2025, and down 5.81% on a QoQ basis from $96.1 million in Q4 2025.
Heron Therapeutics (HRTX) Total Current Liabilities (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Total Current Liabilities data on file, last reported at $90.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 2.21% year-over-year to $90.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90.5 million (up 2.21% YoY) and the FY2025 annual result came in at $96.1 million, up 8940.26% from the prior year.
- Total Current Liabilities slipped to $90.5 million in Q1 2026, from $96.1 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $258.6 million in Q2 2025 to a low of $415000.0 in Q4 2023.
- A 5-year average of $87.6 million and a median of $86.7 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 14527.89% — and 2023, when it tumbled 99.5%.
- Tracing HRTX's Total Current Liabilities over 5 years: stood at $82.4 million in 2022, then plunged by 99.5% to $415000.0 in 2023, then surged by 156.14% to $1.1 million in 2024, then jumped by 8940.26% to $96.1 million in 2025, then slipped by 5.81% to $90.5 million in 2026.
- The last three Total Current Liabilities figures came in at $90.5 million (Q1 2026), $96.1 million (Q4 2025), and $89.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 630.93 Mn |
| 10 | Heron Therapeutics | 60.22 Mn | 17.56 Mn | 26.09 Mn | 92.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 92.15 Mn |
| Mar 31, 2026 | 90.52 Mn |
| Dec 31, 2025 | 96.10 Mn |
| Sep 30, 2025 | 89.71 Mn |
| Jun 30, 2025 | 258.60 Mn |
| Mar 31, 2025 | 88.56 Mn |
| Dec 31, 2024 | 1.06 Mn |
| Sep 30, 2024 | 85.54 Mn |
| Jun 30, 2024 | 80.32 Mn |
| Mar 31, 2024 | 75.38 Mn |
| Dec 31, 2023 | 415,000.00 |
| Sep 30, 2023 | 79.75 Mn |
| Jun 30, 2023 | 86.72 Mn |
| Mar 31, 2023 | 77.90 Mn |
| Dec 31, 2022 | 82.36 Mn |
| Sep 30, 2022 | 93.88 Mn |
| Jun 30, 2022 | 109.50 Mn |
| Mar 31, 2022 | 93.00 Mn |
| Dec 31, 2021 | 563,000.00 |
| Sep 30, 2021 | 72.30 Mn |